Stoke Therapeutics SEC Filings

Upstart Holdings, Inc. (UPST) – Form 144 insider notice

Insider Natalia Mirgorodskaya has filed to sell up to 6,533 common shares through Charles Schwab on or about 07/02/2025. At the reference price used in the filing, the transaction is valued at roughly $457,674. The shares were obtained the same day via an employee stock-option cashless exercise. Mirgorodskaya also disclosed two prior sales in the last three months—764 shares for $35,874 on 05/20/2025 and 1,340 shares for $59,215 on 05/23/2025.

With 95,144,858 shares outstanding, the proposed sale represents approximately 0.007 % of total shares, indicating a limited potential impact on the float. The filer certified that no undisclosed adverse information is known, in accordance with Rule 144 requirements.

Everi Holdings Inc. (EVRI) filed Post-Effective Amendment No. 1 to twelve prior Form S-8 registration statements covering an aggregate of approximately 48.6 million shares of common stock reserved for various equity compensation plans dating back to 2006. The amendment formally deregisters all unsold shares under those statements.

The action follows the 1 July 2025 closing of a multi-party transaction in which funds managed by affiliates of Apollo Global Management (through Voyager Parent, LLC) simultaneously acquired Everi and International Game Technology PLC’s Gaming & Digital business:

• IGT transferred its Gaming & Digital assets to Ignite Rotate LLC ("Spinco") and related liabilities (the “Separation”).
• Buyer purchased all Spinco units and IGT Canada Solutions ULC shares.
• Voyager Merger Sub, Inc. merged with and into Everi, making Everi a wholly owned subsidiary of Buyer (the “Merger”).

Because Everi’s common stock will be delisted and deregistered under Section 12(b) of the Exchange Act, the company is terminating all outstanding securities offerings. Upon effectiveness of this filing, no shares remain registered for sale under the referenced S-8 statements.

Amendment No. 5 to Schedule 13D updates the ownership position of the reporting group — Skorpios Trust, Montrago Trustees Ltd., Blue Horizon Enterprise Ltd. and Ezbon International Ltd. — in Stoke Therapeutics (STOK).

The group now reports beneficial ownership of roughly 6.23 million shares, or 11.4 % of the 54.6 million shares outstanding as disclosed in STOK’s 30 April 2025 10-Q. Current individual blocks are:

• Blue Horizon: 2,967,621 shares (5.4 %) with shared voting/dispositive power
• Montrago Trustees & Skorpios Trust: 3,256,181 shares each, reflecting the same 6 % stake held jointly
• Ezbon International: 288,560 shares (0.5 %)

Key event: On 18 June 2025 Ezbon sold 650,000 shares at $11.00 in an open-market trade, cutting its holdings by ~69 % and raising about $7.2 million. No other trades were reported within the past 60 days.

A new Joint Filing Agreement dated 23 June 2025 is filed as Exhibit 1. Aside from Ezbon’s sale, prior disclosures remain unchanged.

While the group continues to exceed the 10 % threshold, Ezbon’s sizable disposal may signal reduced conviction or liquidity needs, and could introduce incremental supply pressure if additional sales follow. Investors should monitor forthcoming filings for further changes to this concentrated insider position.

Stoke Therapeutics (STOK) – Form 3 initial beneficial ownership disclosure

Chief Patient Officer Jason Hoitt has filed his first Section 16 statement. He directly owns 1,802 common shares of Stoke Therapeutics. In addition, he holds 480,000 employee stock options across four grants: 265,000 options at $12.21 expiring 04/14/2034; 65,000 at $14.25 expiring 08/14/2034; 60,000 at $8.33 expiring 03/19/2035; and 90,000 at $11.70 expiring 06/15/2035. Vesting schedules follow the standard 25% cliff after one year, with the remainder vesting monthly, subject to continued employment. Hoitt was also granted 40,000 restricted stock units (RSUs) that vest 25% annually starting 03/15/2026.

The filing is informational only—no shares were bought or sold. While the equity package is meaningful for the executive, it represents a small fraction of the company’s total shares outstanding and is unlikely to move the market. Nonetheless, the disclosure demonstrates alignment of management incentives with shareholder interests.